Compugen Ltd (CGEN, Financial), a clinical-stage therapeutic discovery and development company, saw its stock rise by 5% to $1.66 with a trading volume of 315,350 shares. The company's recent earnings report shows revenue of $17.13 million, net profit of $1.28 million, and earnings per share of $0.01. The gross profit was $13.53 million, with a price-to-earnings ratio of 54.33. Currently, there are no institutional ratings for CGEN.
In the biotechnology sector, which increased by 0.18%, other notable stocks include Psyence Biomedical Ltd and Adc Therapeutics Sa, which showed significant gains. Compugen's focus is on cancer immunotherapy, with projects like COM701 and COM902 targeting immune checkpoints.
